<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Deals and M&amp;A</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Roche to acquire Pathai for up to $1.05B</title>
      <description>
        <![CDATA[Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to strengthen its position in digital pathology and enhance its biopharma services. The move builds on a partnership established between the two companies in 2021, and expanded in 2024, to include the development of AI-enabled companion diagnostic algorithms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730966</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730966-roche-to-acquire-pathai-for-up-to-105b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Roche-building.webp?t=1698088417" type="image/jpeg" medium="image" fileSize="310241">
        <media:title type="plain">Roche building</media:title>
        <media:description type="plain">Credit: F. Hoffmann-La Roche Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst</title>
      <description>
        <![CDATA[Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition gives Angelini ownership of three marketed drugs for treating epilepsy and neuromuscular diseases that had combined sales of $589 million in 2025, a 19.8% increase over 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730965</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730965-italys-angelini-pays-41b-cash-for-rare-disease-specialist-catalyst</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neuro-illustration.webp?t=1628534498" type="image/png" medium="image" fileSize="616001">
        <media:title type="plain">Neurology illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK licenses siRNA asset in $1B deal for Siranbio</title>
      <description>
        <![CDATA[In a deal that could be worth up to $1 billion for Suzhou Siran Biotechnology Co. Ltd. (Siranbio), GSK plc licensed exclusive worldwide rights to the siRNA oligonucleotide SA-030, which has recently entered phase I trials for cardiometabolic disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730864</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730864-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Resmed boosts sleep health portfolio with Noctrix buy</title>
      <description>
        <![CDATA[Resmed Corp. has agreed to acquire Noctrix Health Inc. for $340 million, boosting its sleep health portfolio. Noctrix has developed Nidra, a wearable neuromodulation device which treats restless legs syndrome (RLS) without disrupting sleep. With RLS impacting approximately 7% of adults globally, including about 17 million people in the U.S., the technology offers a non-drug option that could potentially treat a significant proportion of this patient population.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730863</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730863-resmed-boosts-sleep-health-portfolio-with-noctrix-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Noctrix-Health-Nidra-system-5-6.webp?t=1778095493" type="image/jpeg" medium="image" fileSize="97350">
        <media:title type="plain">Noctrix Health Nidra system</media:title>
        <media:description type="plain">Nidra, a wearable neuromodulation device for restless legs syndrome. Credit: Noctrix Health Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayer buying Perfuse for $300M up front in potential $2.45B deal </title>
      <description>
        <![CDATA[In its first substantial M&A transaction since 2021, Bayer AG is buying Perfuse Therapeutics Inc., a firm that has operated quietly, though it reported positive midstage data last year for PER-001, an endothelin antagonist, in glaucoma and diabetic retinopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730862</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730862-bayer-buying-perfuse-for-300m-up-front-in-potential-245b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-financial-charts.webp?t=1685051887" type="image/jpeg" medium="image" fileSize="207505">
        <media:title type="plain">Eye and financial charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730925</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730925-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s new IIT rules could reshape early stage drug development </title>
      <description>
        <![CDATA[China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more multinational companies to conduct IITs in China, panelists said during the Chinabio Partnering Forum in Shanghai April 28-29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730924</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730924-chinas-new-iit-rules-could-reshape-early-stage-drug-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>Madrigal expands MASH pipeline in potential $1B Arrowhead deal</title>
      <description>
        <![CDATA[Three years after Johnson & Johnson handed back rights to an siRNA candidate targeting a genetic driver of metabolic dysfunction-associated steatohepatitis (MASH), Arrowhead Pharmaceuticals Inc. found a new partner in Madrigal Pharmaceuticals Inc., a firm that markets the first U.S. FDA-approved MASH drug, Rezdiffra (resmetirom), and has been building a pipeline in the space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730851</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730851-madrigal-expands-mash-pipeline-in-potential-1b-arrowhead-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-and-DNA.webp?t=1602177503" type="image/png" medium="image" fileSize="311397">
        <media:title type="plain">Liver and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730878</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730878-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730749</guid>
      <pubDate>Thu, 30 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730749-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Dermatology specialist Leo Pharma makes a $50M move into gene therapy</title>
      <description>
        <![CDATA[Dermatology specialist Leo Pharma A/S is moving into gene therapy with the $50 million acquisition of Replay Holdings LLC, a seed-stage company that is developing high capacity herpes simplex virus vectors to treat rare inherited diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730748</guid>
      <pubDate>Thu, 30 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730748-dermatology-specialist-leo-pharma-makes-a-50m-move-into-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-anatomy-and-DNA.webp?t=1777580724" type="image/jpeg" medium="image" fileSize="187452">
        <media:title type="plain">Skin anatomy and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Astrazeneca exercises option for Pinetree’s PTX-299</title>
      <description>
        <![CDATA[Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730793</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730793-astrazeneca-exercises-option-for-pinetrees-ptx-299</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/dollar-idea-lightbulb.webp?t=1588794062" type="image/png" medium="image" fileSize="331510">
        <media:title type="plain">Dollar sign in lightbulb</media:title>
      </media:content>
    </item>
    <item>
      <title>Caredx to acquire Naveris for up to $260 million</title>
      <description>
        <![CDATA[Caredx Inc. has agreed to acquire Naveris Inc., a precision oncology diagnostics company, for up to $260 million, as part of its strategy to accelerate growth. The acquisition comes as Caredx, an organ transplant diagnostic firm, reshapes its portfolio, expanding its oncology profile while recently divesting its lab products business.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730687</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730687-caredx-to-acquire-naveris-for-up-to-260-million</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-AI-diagnostic.webp?t=1745257620" type="image/jpeg" medium="image" fileSize="265878">
        <media:title type="plain">Cancer diagnostic illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s new IIT rules could reshape early stage drug development </title>
      <description>
        <![CDATA[China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more multinational companies to conduct IITs in China, panelists said during the Chinabio Partnering Forum in Shanghai April 28-29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730684</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730684-chinas-new-iit-rules-could-reshape-early-stage-drug-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>Chiesi snags on-demand HAE drug in $1.9B Kalvista buy </title>
      <description>
        <![CDATA[In its largest acquisition to date, Chiesi Group is buying Kalvista Pharmaceuticals Inc. for $27 per share, a roughly 40% premium to the previous day’s closing price, putting the total deal value at about $1.9 billion. In return, the Italian pharma firm adds to its rare disease franchise Kalvista’s recently approved hereditary angioedema (HAE) drug, plasma kallikrein inhibitor Ekterly (sebetralstat), which has gotten off to a strong commercial launch as the only orally available, on-demand treatment for HAE.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730681</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730681-chiesi-snags-on-demand-hae-drug-in-19b-kalvista-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Ekterly.webp?t=1751908254" type="image/png" medium="image" fileSize="221805">
        <media:title type="plain">Ekterly pill and packaging</media:title>
        <media:description type="plain">Credit: Kalvista Pharmaceuticals Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730787</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>China partnerships lead biopharma deal surge in Q1 2026</title>
      <description>
        <![CDATA[Biopharma deal value reached $79.22 billion in the first quarter (Q1) 2026, marking a strong start to the year and an increase of about 17% from $67.6 billion in Q1 2025 and similar to $78.93 billion in Q4 2025. The total is the highest first-quarter tally in recent years, and the highest quarter since Q4 2025 brought $80.65 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730784</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730784-china-partnerships-lead-biopharma-deal-surge-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Chart-of-arrows-pointing-upward.webp?t=1739225283" type="image/jpeg" medium="image" fileSize="46079">
        <media:title type="plain">Chart of arrows pointing upward</media:title>
      </media:content>
    </item>
    <item>
      <title>Takeda takes rusfertide’s US rights; Protagonist opts out for cash </title>
      <description>
        <![CDATA[More than two years after signing a $1.7 billion deal with Takeda Pharmaceutical Co. Ltd., Protagonist Therapeutics Inc. has opted out of a 50-50 U.S. profit-and-loss sharing arrangement for its hepcidin mimetic peptide, rusfertide, a priority review drug developed to treat adults with polycythemia vera.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730674</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730674-takeda-takes-rusfertides-us-rights-protagonist-opts-out-for-cash</link>
    </item>
    <item>
      <title>Thermo Fisher sells microbiology business for $1B</title>
      <description>
        <![CDATA[Thermo Fisher Scientific Inc. agreed to sell its microbiology business to Astorg, a private equity firm, for approximately $1.075 billion, consisting of cash and a $50 million seller note. The business unit provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730672</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730672-thermo-fisher-sells-microbiology-business-for-1b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gloved-hand-holding-petri-dish.webp?t=1594325173" type="image/png" medium="image" fileSize="413731">
        <media:title type="plain">Gloved hand holding petri dish in lab</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinese biotechs gain leverage as partners in dealmaking</title>
      <description>
        <![CDATA[China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said during the Chinabio Partnering Forum in Shanghai April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730670</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730670-chinese-biotechs-gain-leverage-as-partners-in-dealmaking</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Chinabio-2026-partnering-4-28.webp?t=1777394174" type="image/jpeg" medium="image" fileSize="198615">
        <media:title type="plain">Chinabio 2026 partnering </media:title>
        <media:description type="plain">China’s evolution in the dealmaking arena was the hot topic of discussion on the first day of the Chinabio Partnering Forum.</media:description>
      </media:content>
    </item>
    <item>
      <title>Lilly buying Ajax for up to $2.3B for next-gen JAK assets</title>
      <description>
        <![CDATA[Eli Lilly and Co. is acquiring Ajax Therapeutics Inc. for up to $2.3 billion in cash, gaining access to next-generation JAK inhibitors for patients with myeloproliferative neoplasms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730647</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730647-lilly-buying-ajax-for-up-to-23b-for-next-gen-jak-assets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Eli-Lilly-signage.webp?t=1767910760" type="image/jpeg" medium="image" fileSize="673005">
        <media:title type="plain">Eli Lilly logo atop Lilly Biotechnology Center campus in San Diego, Calif.</media:title>
        <media:description type="plain">Credit: MichaelVi - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>UK biotech funding in Q1 2026 hints a recovery is in the offing</title>
      <description>
        <![CDATA[The funding momentum that was building at the end of 2025 was maintained in the first quarter (Q1) of 2026, with a rebound in venture capital (VC) investment in U.K. biotech. Overall investment in the sector during Q1 was £552 million (US$748 million), of which £516 million was in VC.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730644</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730644-uk-biotech-funding-in-q1-2026-hints-a-recovery-is-in-the-offing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pill-with-British-pound-sign.webp?t=1627069868" type="image/png" medium="image" fileSize="33159">
        <media:title type="plain">Pill with British pound sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730643</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest </title>
      <description>
        <![CDATA[A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything from epilepsy and narcolepsy to post-traumatic stress disorder and hyperphagia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730616</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730616-neuro-deals-aplenty-ucbs-1b-takeover-of-neurona-the-latest</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Epileptic-brain.webp?t=1648507237" type="image/png" medium="image" fileSize="319894">
        <media:title type="plain">Epileptic brain and abnormal EEG wave discharges</media:title>
      </media:content>
    </item>
    <item>
      <title>China partnerships lead biopharma deal surge in Q1 2026</title>
      <description>
        <![CDATA[Biopharma deal value reached $79.22 billion in the first quarter (Q1) 2026, marking a strong start to the year and an increase of about 17% from $67.6 billion in Q1 2025 and similar to $78.93 billion in Q4 2025. The total is the highest first-quarter tally in recent years, and the highest quarter since Q4 2025 brought $80.65 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730613</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730613-china-partnerships-lead-biopharma-deal-surge-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Chart-of-arrows-pointing-upward.webp?t=1739225283" type="image/jpeg" medium="image" fileSize="46079">
        <media:title type="plain">Chart of arrows pointing upward</media:title>
      </media:content>
    </item>
    <item>
      <title>A free gene therapy? Regeneron’s Otarmeni approved for hearing loss</title>
      <description>
        <![CDATA[Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals Inc.’s DB-OTO, an AAV-mediated gene therapy. Branded Otarmeni (lunsotogene parvec), it is cleared specifically for hearing loss caused by variants in the otoferlin gene.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730604</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730604-a-free-gene-therapy-regenerons-otarmeni-approved-for-hearing-loss</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/ENT/Boy-cupping-ear-with-soundwaves.webp?t=1776979575" type="image/jpeg" medium="image" fileSize="599085">
        <media:title type="plain">Boy cupping ear with soundwave graphic</media:title>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730574</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Aiming to Jimi the regulatory lock in psychedelics</title>
      <description>
        <![CDATA[The quest by psychedelic drugs for full legitimacy in the pharmaceutical world has seen marked progress as well as (fewer) setbacks of late, and developers are hopeful that an important corner has been turned.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730466</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730466-aiming-to-jimi-the-regulatory-lock-in-psychedelics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Psychedelic-pills.webp?t=1652215818" type="image/png" medium="image" fileSize="256746">
        <media:title type="plain">Pills shaded in psychedelic colors</media:title>
      </media:content>
    </item>
    <item>
      <title>Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal</title>
      <description>
        <![CDATA[The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as much as $7 billion in cash, including an up-front payment of $3.25 billion, with the rest coming if clinical, regulatory and commercial goals are reached.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730467</guid>
      <pubDate>Mon, 20 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730467-pleased-to-own-ya-kelonia-lillys-7b-car-t-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Gold-encircled-handshake.webp?t=1767911999" type="image/jpeg" medium="image" fileSize="530529">
        <media:title type="plain">Gold-encircled handshake</media:title>
      </media:content>
    </item>
  </channel>
</rss>
